Literature DB >> 25801126

Emerging preclinical animal models for FSHD.

Angela Lek1, Fedik Rahimov2, Peter L Jones3, Louis M Kunkel2.   

Abstract

Facioscapulohumeral dystrophy (FSHD) is a unique and complex genetic disease that is not entirely solved. Recent advances in the field have led to a consensus genetic premise for the disorder, enabling researchers to now pursue the design of preclinical models. In this review we explore all available FSHD models (DUX4-dependent and -independent) for their utility in therapeutic discovery and potential to yield novel disease insights. Owing to the complex nature of FSHD, there is currently no single model that accurately recapitulates the genetic and pathophysiological spectrum of the disorder. Existing models emphasize only specific aspects of the disease, highlighting the need for more collaborative research and novel paradigms to advance the translational research space of FSHD.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  DUX4; facioscapulohumeral dystrophy; muscular dystrophy

Mesh:

Substances:

Year:  2015        PMID: 25801126      PMCID: PMC4424175          DOI: 10.1016/j.molmed.2015.02.011

Source DB:  PubMed          Journal:  Trends Mol Med        ISSN: 1471-4914            Impact factor:   11.951


  69 in total

1.  Expression profiling of FSHD muscle supports a defect in specific stages of myogenic differentiation.

Authors:  Sara T Winokur; Yi-Wen Chen; Peter S Masny; Jorge H Martin; Jeffrey T Ehmsen; Stephen J Tapscott; Silvere M van der Maarel; Yukiko Hayashi; Kevin M Flanigan
Journal:  Hum Mol Genet       Date:  2003-09-30       Impact factor: 6.150

2.  Asymptomatic carriers and gender differences in facioscapulohumeral muscular dystrophy (FSHD).

Authors:  M M O Tonini; M R Passos-Bueno; A Cerqueira; S R Matioli; R Pavanello; M Zatz
Journal:  Neuromuscul Disord       Date:  2004-01       Impact factor: 4.296

3.  Contractions of D4Z4 on 4qB subtelomeres do not cause facioscapulohumeral muscular dystrophy.

Authors:  Richard J F L Lemmers; Mariëlle Wohlgemuth; Rune R Frants; George W Padberg; Eva Morava; Silvere M van der Maarel
Journal:  Am J Hum Genet       Date:  2004-10-04       Impact factor: 11.025

4.  FRG2, an FSHD candidate gene, is transcriptionally upregulated in differentiating primary myoblast cultures of FSHD patients.

Authors:  T Rijkers; G Deidda; S van Koningsbruggen; M van Geel; R J L F Lemmers; J C T van Deutekom; D Figlewicz; J E Hewitt; G W Padberg; R R Frants; S M van der Maarel
Journal:  J Med Genet       Date:  2004-11       Impact factor: 6.318

Review 5.  Facioscapulohumeral dystrophy.

Authors:  Shree Pandya; Wendy M King; Rabi Tawil
Journal:  Phys Ther       Date:  2007-11-06

6.  DUX4 activates germline genes, retroelements, and immune mediators: implications for facioscapulohumeral dystrophy.

Authors:  Linda N Geng; Zizhen Yao; Lauren Snider; Abraham P Fong; Jennifer N Cech; Janet M Young; Silvere M van der Maarel; Walter L Ruzzo; Robert C Gentleman; Rabi Tawil; Stephen J Tapscott
Journal:  Dev Cell       Date:  2011-12-29       Impact factor: 12.270

7.  Abnormal expression of mu-crystallin in facioscapulohumeral muscular dystrophy.

Authors:  Patrick W Reed; Andrea M Corse; Neil C Porter; Kevin M Flanigan; Robert J Bloch
Journal:  Exp Neurol       Date:  2007-03-21       Impact factor: 5.330

8.  DUX4c is up-regulated in FSHD. It induces the MYF5 protein and human myoblast proliferation.

Authors:  Eugénie Ansseau; Dalila Laoudj-Chenivesse; Aline Marcowycz; Alexandra Tassin; Céline Vanderplanck; Sébastien Sauvage; Marietta Barro; Isabelle Mahieu; Axelle Leroy; India Leclercq; Véronique Mainfroid; Denise Figlewicz; Vincent Mouly; Gillian Butler-Browne; Alexandra Belayew; Frédérique Coppée
Journal:  PLoS One       Date:  2009-10-15       Impact factor: 3.240

Review 9.  Facioscapulohumeral dystrophy: the path to consensus on pathophysiology.

Authors:  Rabi Tawil; Silvère M van der Maarel; Stephen J Tapscott
Journal:  Skelet Muscle       Date:  2014-06-10       Impact factor: 4.912

10.  DUX4 binding to retroelements creates promoters that are active in FSHD muscle and testis.

Authors:  Janet M Young; Jennifer L Whiddon; Zizhen Yao; Bhavatharini Kasinathan; Lauren Snider; Linda N Geng; Judit Balog; Rabi Tawil; Silvère M van der Maarel; Stephen J Tapscott
Journal:  PLoS Genet       Date:  2013-11-21       Impact factor: 5.917

View more
  27 in total

1.  Model systems of DUX4 expression recapitulate the transcriptional profile of FSHD cells.

Authors:  Sujatha Jagannathan; Sean C Shadle; Rebecca Resnick; Lauren Snider; Rabi N Tawil; Silvère M van der Maarel; Robert K Bradley; Stephen J Tapscott
Journal:  Hum Mol Genet       Date:  2016-10-15       Impact factor: 6.150

Review 2.  FSHD Therapeutic Strategies: What Will It Take to Get to Clinic?

Authors:  Charis L Himeda; Peter L Jones
Journal:  J Pers Med       Date:  2022-05-25

Review 3.  Therapeutic Approaches in Facioscapulohumeral Muscular Dystrophy.

Authors:  Justin Cohen; Alec DeSimone; Monkol Lek; Angela Lek
Journal:  Trends Mol Med       Date:  2020-10-19       Impact factor: 11.951

4.  Endogenous DUX4 expression in FSHD myotubes is sufficient to cause cell death and disrupts RNA splicing and cell migration pathways.

Authors:  Amanda M Rickard; Lisa M Petek; Daniel G Miller
Journal:  Hum Mol Genet       Date:  2015-08-05       Impact factor: 6.150

Review 5.  Genome engineering: a new approach to gene therapy for neuromuscular disorders.

Authors:  Christopher E Nelson; Jacqueline N Robinson-Hamm; Charles A Gersbach
Journal:  Nat Rev Neurol       Date:  2017-09-29       Impact factor: 42.937

Review 6.  Facioscapulohumeral dystrophy: activating an early embryonic transcriptional program in human skeletal muscle.

Authors:  Amy E Campbell; Andrea E Belleville; Rebecca Resnick; Sean C Shadle; Stephen J Tapscott
Journal:  Hum Mol Genet       Date:  2018-08-01       Impact factor: 6.150

7.  DUX4 induces a transcriptome more characteristic of a less-differentiated cell state and inhibits myogenesis.

Authors:  Paul Knopp; Yvonne D Krom; Christopher R S Banerji; Maryna Panamarova; Louise A Moyle; Bianca den Hamer; Silvère M van der Maarel; Peter S Zammit
Journal:  J Cell Sci       Date:  2016-10-15       Impact factor: 5.285

8.  A Human Pluripotent Stem Cell Model of Facioscapulohumeral Muscular Dystrophy-Affected Skeletal Muscles.

Authors:  Leslie Caron; Devaki Kher; Kian Leong Lee; Robert McKernan; Biljana Dumevska; Alejandro Hidalgo; Jia Li; Henry Yang; Heather Main; Giulia Ferri; Lisa M Petek; Lorenz Poellinger; Daniel G Miller; Davide Gabellini; Uli Schmidt
Journal:  Stem Cells Transl Med       Date:  2016-05-23       Impact factor: 6.940

Review 9.  Molecular and cellular basis of genetically inherited skeletal muscle disorders.

Authors:  James J Dowling; Conrad C Weihl; Melissa J Spencer
Journal:  Nat Rev Mol Cell Biol       Date:  2021-07-13       Impact factor: 94.444

10.  A cross sectional study of two independent cohorts identifies serum biomarkers for facioscapulohumeral muscular dystrophy (FSHD).

Authors:  Lisa M Petek; Amanda M Rickard; Christopher Budech; Sandra L Poliachik; Dennis Shaw; Mark R Ferguson; Rabi Tawil; Seth D Friedman; Daniel G Miller
Journal:  Neuromuscul Disord       Date:  2016-04-22       Impact factor: 4.296

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.